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ABSTRACT 
Introduction 
Ninety percent of the world’s 2.1 million HIV-infected children live in sub-Saharan Africa 
and 2.5% of South African children are living with HIV. As HIV care programmes scale-
up, loss to follow-up is on the rise. 
The aim of the study was to determine the rate of loss to follow-up (LTFU) in children 
receiving antiretroviral treatment and to identify baseline characteristics associated with 
LTFU and temporary interruption of follow-up (TIFU) in these children. The reasons 
given by caregivers for clinic non-attendance were also explored. 
Materials and Methods 
The study is a retrospective analysis of data that was prospectively collected as part of 
routine clinical care of HIV-infected children at the Harriet Shezi Children’s Clinic in 
Soweto, Johannesburg. Children aged 12 years or less that had initiated highly active 
antiretroviral therapy (HAART) at the clinic between 1 April 2004 and 31 December 
2008 and had been on treatment for at least 3 months, were included in the study. 
Follow-up was censored on 30 September 2009. Kaplan-Meier methods were used to 
estimate time to LTFU or TIFU. Cox proportional hazards models were fitted to 
investigate associations between baseline characteristics and LTFU as well as TIFU. 
Pie charts and frequency tables were used to describe reasons for clinic non-
attendance. 
Results 
Of the 2536 children included in the study, 174 (6.86%) were LTFU at the end the study 
period. The cumulative probabilities of LTFU at 6 months, 12 months and 2 years were 
found to be 0.9% (95% CI 0.67 – 1.47), 2.85% (95% CI 2.26 – 3.59) and 5.22% (95% CI 
4.36 – 6.25) respectively. Independent predictors of LTFU were WHO clinical stage 3 or 
4 [HR 2.14 (95% CI 1.22 – 3.73) p=0.026] and younger age [HR 0.91 (95% CI 0.84 – 
0.99) p=0.008] the hazard of LTFU decreasing by 9% for every 1 year increase in age. 
A total of 338(13.32%) children interrupted follow-up for at least 6months before 
returning to care. Factors independently associated with TIFU were taking a protease 
inhibitor based regimen [HR 1.67 (95% CI 1.18 – 2.35) p=0.004] and being moderately 
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underweight [HR 0.66 (95% CI 0.45 – 0.99) p=0.043] was protective. Social reasons 
(46.43%) and financial reasons (10.05%) together accounted for the majority of reasons 
given for clinic non-attendance. Caregiver-related problems (53.22%) were the 
commonest social reasons given for missing a clinic visit. 
Conclusions 
These LTFU rates are much lower than those found in studies where children on 
HAART duration of less than 3 months were included and may reflect on true LTFU with 
minimal effect of unreported early mortality. WHO clinical stage 3 or 4 and younger age 
independently predicted LTFU. Independent predictors of TIFU were moderate 
underweight and being on a PI-based regimen. LTFU is not necessarily permanent with 
most of those who interrupt follow-up returning to care. The main reasons why children 
miss clinic appointments are social. Caregiver-related problems are important reasons 
for clinic non-attendance in children on HAART. 
Recommendations 
Initiating children on HAART in earlier disease stages may reduce LTFU. Strategies to 
improve LTFU need to target younger children and there is need for further research to 
investigate why young children are especially vulnerable to LTFU. Caregivers of 
children who temporarily interrupt follow-up can potentially provide a unique opportunity 
for health workers to learn the true reasons why children get LTFU. Such caregivers 
may also be targeted for more intensive adherence counselling.  Further studies on the 
implications of TIFU on the development of resistance to antiretroviral drugs are 
needed. Primary caregivers of children need to be encouraged to identify secondary 
caregivers who can bring the child to the clinic in the event that the primary caregiver is 
unable to bring the child.   
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Chapter 1: Introduction 
The chapter begins with a general overview of the burden of HIV in sub-Saharan Africa 
and in South Africa. The implications of the scale-up of antiretroviral treatment in HIV 
care treatment programmes on loss to follow-up are explored. The published literature 
on loss to follow-up is reviewed and the chapter ends with a description of the aims and 
objectives of the study. 
1.1 Background 
Sub-Saharan Africa (SSA) is home to 90% of the world’s 2.1 million HIV-infected 
children and of all the people living with HIV in sub-Saharan Africa, 10% of them are 
children (1). In South Africa at the end of 2007, 280 000 children were infected with HIV 
and the prevalence of HIV in children aged between 2 and 14 years was 2.5% (1.9-
3.5%) (2, 3). 
 Despite having such a high disease burden, the increasing national and political 
commitment to the treatment and care of HIV in South Africa is encouraging. The 
National Strategic Plan for HIV&AIDS and STIs 2007-2011 (NSP) aims to provide a 
comprehensive HIV care and treatment package to 80% of people living with HIV by 
2011 (4).According to the South Africa Country Progress Report on the Declaration of 
Commitment on HIV/AIDS released in March 2010, there has been some progress with 
81% of children and 55% of adults in need of HAART receiving treatment at the end of 
November 2009(4). 
Enhancing Children’s HIV Outcomes (ECHO) is a non-profit organisation which 
supports the South African department of health in the paediatric HIV roll-out 
programme at several sites in South Africa. The study is set at the Chris Hani 
Baragwanath Hospital Harriet Shezi Children’s Clinic (HSCC) in Soweto which is 
ECHO’s flagship clinic. The HSCC started providing government-sourced antiretroviral 
treatment in April of 2004 and the cumulative number of children ever started on 
treatment at the HSCC as of June 2010 was 3577.  
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1.2 Statement of the Problem 
 
The initial hope, improvement of survival and quality of life associated with highly active 
antiretroviral therapy (HAART) in people infected with HIV faces the new challenge of 
retaining patients in long term care. LTFU may potentially lead to inaccurate mortality 
estimates (5), making assessment of the effectiveness of HIV care programmes 
problematic. Adult HIV care programs in sub-Saharan Africa are reportedly retaining 
only about 60% of their patients in the first two years (6). 
While children in HIV care programs have a much higher retention than adults, a rise in 
LTFU has been observed as paediatric HIV care programmes scale-up (7-9). A trend of 
increase in LTFU over time was observed in a pooled analysis of the 16 paediatric HIV 
care programmes in sub-Saharan Africa which form the Kids’ Antiretroviral Treatment in 
Lower-Incomes Countries (KIDS-ART-LINC) Collaboration. The risk of LTFU was 2.8% 
(95%CI: 1.9 to4.1) at 6 months, 4.6% (95%CI: 3.4 to 6.2) at 1 year, and 8.4% (95%CI: 
6.5 to 10.7) at 2 years (7). 
In a study of the outcomes of the South African national paediatric antiretroviral 
treatment programme which analysed data from 7 public sector ART programmes in 
Gauteng, Western Cape and Kwazulu-Natal  provinces, the retention at 3 years after 
initiation was 81.4%(95% CI 80.1-82.6)(8). Of concern however, is the increase in LTFU 
over time. In the same study, LTFU at 1 year after initiation was much higher in children 
who started ART during or after 2006[8.2% (95% CI 7.1-9.4)] compared to those who 
had started ART before 2004 [2.2 %( 95%CI 1.1-4.7)] (8).  
1.3 Justification 
The study of LTFU and other treatment outcomes in HIV care has been used to monitor 
and improve programme effectiveness, using patient retention as a measure of quality 
of care (10). Some patients who are deemed LTFU are misclassified deaths (11, 12), 
unreported transfers (13) and temporary treatment interrupters (11). It is therefore 
important to examine the risk factors and reasons for LTFU in order to make appropriate 
recommendations for patient retention in HIV care programmes. 
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Now that the scaling-up of antiretroviral treatment has gained momentum in South 
Africa, the question is not only how many children can be put on treatment, but also how 
many can be retained in care.  
While several studies have been done in South Africa on the reasons, characteristics, 
the extent and contributing factors of LTFU in adults on HAART (14, 15), there is limited 
data on the reasons for LTFU and the predictors of LTFU in children on HAART in 
South Africa.   
1.4 Literature Review 
1.4.1 The Rate of Loss to Follow-up in Paediatric HIV Care Programmes 
Studies of patient outcomes in African paediatric HIV care programmes have shown 
varying rates of LTFU. In the KIDS-ART-LINC collaboration which included paediatric 
cohorts from Benin, Ivory Coast, Ghana, Burundi, Zimbabwe, Rwanda, Uganda, Kenya 
and Zambia, overall cumulative probabilities of LTFU at 1 year and 2 years of follow-up 
were 5.0% (95%CI: 4.1 to 6.1) and 10.3% (95%CI: 8.9 to 11.9)  respectively(7). The 
International epidemiologic Databases to Evaluate AIDS in Southern Africa (IeDEA-SA) 
reported a one-year LTFU rate of 7% in a pooled analysis of 10 paediatric ART 
programmes from South Africa, Malawi, Mozambique and Zimbabwe (5). A study of 
outcomes of the South African national paediatric ART which was also done by the 
IeDEA-SA collaboration reported a one-year LTFU rate of 2.2%(95%CI 1.1-4.7) for 
patients who initiated ART before 2004.  In comparison, the one-year LTFU rate of 
patients who had started ART during or after 2006 in the same study was much higher 
[8.2% (95% CI 7.1-9.4)](8). Smaller studies done in South Africa have reported lower 
LTFU rates. A study done in Cape Town to evaluate outcomes of children on different 
ART regimens reported overall LTFU rates of 1.3% (95% CI 0.5-3.4) at 1 year and 3.7% 
(95% CI 1.9-7.2) at 2 years(16). Sinikithemba clinic in KwaZulu-Natal has a family 
centred model of care and reported LTFU rate of 0% within a median follow-up time of 8 
months (17). 
1.4.2 Loss to follow-up and Mortality 
Assessing attrition or LTFU in HIV care programs has been clouded by high mortality 
rates with unreported mortality contributing to LTFU. In a study done in Northern Malawi 
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to determine the true outcomes of adult patients who were deemed LTFU, 50% of them 
had actually died and 27% could not be traced (18). A study on the characteristics and 
outcomes of adults lost to follow-up in Johannesburg, South Africa showed that 16.4% 
of patients were LTFU (defined as missing a scheduled visit for a minimum of 6 weeks) 
during the follow-up period of 15 months. Just under 70% of all those LTFU were 
traced, and nearly half of all those traced had died (15). Linkage of vital registration and 
clinic data of patients who were LTFU at Themba Lethu clinic in Johannesburg, showed 
that 37.2% of patients traced had actually died and mortality estimates were adjusted 
from 4.2% to 10.9%(19). 
Most children initiating HAART in resource-poor settings start treatment at advanced 
stages of illness leading to high mortality rates especially in the first 3 months of HAART 
initiation (1, 5, 20, 21). Unreported deaths may inflate LTFU and conversely 
underestimate mortality. Characteristics of children who were lost to follow-up were 
similar to those of deceased children in a retrospective case cohort study done in 
Malawi to investigate predictors of mortality and LTFU among children taking HAART 
(20). Deceased children had similar median ART duration, mean age, mean weight and 
CD4 counts with those LTFU. WHO stage 4 was independently associated with both 
mortality and LTFU in these children (20). This suggests that many of those LTFU were 
actually deceased. 
1.4.3 Predictors of Loss to follow-up 
Several studies in paediatric HIV care programmes in resource-poor settings have 
shown an association between clinical markers of disease severity and LTFU (20, 22-
24). Severe immune suppression and severely low weight-for-height z-score were 
associated with LTFU in HIV-infected children attending a comprehensive HIV clinical 
care programme in Western Kenya (23). Severe clinical status was also significantly 
associated with LTFU in the KIDS-ART-LINC collaboration study (7). A diagnosis of 
HIV-related malignancy predicted LTFU in Malawian children during their first year of 
HAART (22). In Haitian children, baseline malnutrition as measured by weight-for-age z-
score (median WAZ -3, IQR -3.7 to -1.8) was more common in children who 
subsequently became LTFU (25). CDC clinical stage C and being treated at a 
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regional/university hospital predicted LTFU among children taking HAART in Thailand 
(24). 
Socioeconomic factors also play a role in LTFU. Children depend on adults for 
treatment adherence and their adherence has been shown to be dependent on 
characteristics of the caregiver and the relationship with the caregiver (26, 27) . 
Caregiver characteristics which have been associated with improved adherence to ART 
in children include biological relationship with the child, caregivers who are on ART, 
caregiver permanence, higher caregiver education and comprehension of ART and 
caregivers who have disclosed their own or the child status to others (27). In the 
Paediatric AIDS Clinical Trials Group (PACTG) 219C cohort study – a multicentre 
clinical trial in the United States, LTFU was associated with lack of participant 
compensation, low caregiver education level, child’s age greater than 15 years, higher 
viral load, children starting school and mothers beginning employment (28). Orphans, 
older children and children receiving food supplementation were less likely to become 
LTFU in HIV-infected children in Western Kenya (23). 
1.4.4 Reasons for Clinic non-attendance 
There are several studies conducted in adults attending HIV care treatment 
programmes in Africa where patients who were LTFU were traced and their actual 
reasons for clinic non-attendance ascertained (14, 15, 18, 29). In rural Uganda, 
common reasons given for clinic non-attendance were lack of transportation or money 
and child or work responsibilities (29). In a study at Themba Lethu clinic in 
Johannesburg, South Africa the most commonly cited reason for clinic non-attendance 
was financial (34%) and 27% of those deemed LTFU had died. Less common reasons 
were transfer to another clinic, using medical aid or private treatment, use of traditional 
medicine and social reasons such as incarceration (14). In a similar study at 
Johannesburg Hospital adult clinic the reasons for being LTFU among those traced, 
other than death were relocation, clinic transfer, hospitalization, medication toxicity and 
financial problems (15). 
In paediatric HIV care programs in SSA, reasons for being LTFU were found to include 
poverty-related factors, frequent relocation, transfers and illness or death of a 
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caregiver(1). There were no studies found which were done in South Africa exploring 
the reasons for non-attendance in paediatric HIV care programmes. 
1.4.5 Conclusion 
Rates of LTFU in paediatric HIV care programmes in SSA range from 1.3% to 8.2% 
after 1 year of follow-up and from 3.7%-10.3% after 2 years of follow-up (5, 8, 16). 
Mortality clouds the assessment of LTFU; many of those deemed LTFU may be dead 
(15, 18). Patients become LTFU because they are dead, rather than that poor 
adherence and clinic non-attendance leads to death. Clinical predictors of LTFU (severe 
malnutrition as measured by weight-for-age and weight-for-height z-scores, WHO stage 
4 or CDC stage C and a diagnosis of HIV-related malignancy) also predict mortality and 
this may reflect unreported deaths (7, 23-25). When patients are actually traced and 
their actual reasons for being LTFU are investigated, mainly socioeconomic reasons are 
given for being LTFU (14, 15, 18, 29). 
1.5 Definition of Terms 
There is no consensus in published literature as to the definition of loss to follow-up 
(30). Depending on the time interval between scheduled visits, LTFU has been defined 
as last patient contact with the care facility for a minimum time period ranging from 
30days to one year (30). Several studies of outcomes in HIV care programmes in 
Southern Africa have defined LTFU as last patient contact with the clinic of more than 6 
months before database closure (5, 8, 29, 31).Children at the HSCC have 3-monthly 
scheduled visits and allowing a time period of at least 6 months before a child could be 
deemed LTFU was appropriate. 
 Kranzer et al. (2010) defined treatment interruption as a patient-initiated episode of 
more than 30 days of stopping ART followed by subsequent resumption of treatment 
(32). Hill et al. (2010) defined temporary LTFU as a gap in care of at least one year (33). 
In this study, the following terms were defined as follows: 
Loss to follow up (LTFU): A child was defined as LTFU if their last date of contact with 
the clinic was more than 6 months before the date of database closure (30 September 
2009) and were not known to have died or transferred(5, 8, 29, 31). 
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Temporary interruption of follow up (TIFU): A child returns to care after at least 6 
months of no contact with the clinic.  
 
1.6 Objectives 
General 
To determine the rate of LTFU in children receiving ART and identify baseline 
characteristics associated with LTFU 
Specific Objectives 
1. To determine the rate of loss to follow-up in children who have been receiving 
HAART for at least 3 months in a large urban paediatric clinic in Johannesburg 
South Africa 
2.  To identify baseline characteristics that independently predict  LTFU in this 
population 
3. To assess baseline characteristics that predict  temporary interruption of follow-
up  
4. To describe the reasons for clinic non-attendance in children on HAART 
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Chapter 2: Materials and Methods 
Introduction 
The study design, site, population and methodology are described in this chapter. The 
methods used for the selection of study participants are explained. The dataset used for 
identification of predictors of LTFU is described. The details of a second dataset used 
for describing reasons for clinic non-attendance are also presented. Definitions of all the 
study variables are given. The measures taken to ensure quality data are also 
described. The chapter ends with a review of the data processing methods and ethical 
considerations. 
2.1 Study Design 
A Retrospective Analytic Cohort Design 
The study is a retrospective analysis of data that was prospectively collected as part of 
routine clinical care of HIV-infected children at the Harriet Shezi Children’s Clinic in 
Soweto. 
2.2 Study Site 
The Harriet Shezi Children’s Clinic is a paediatric HIV rollout site situated at the Chris 
Hani Baragwanath Hospital, an academic tertiary referral hospital in Soweto, 
Johannesburg. The HSCC started offering government-sourced antiretroviral treatment 
on the 1st of April 2004 and a total of 3577 children had been started on antiretroviral 
treatment as of June 2010. All children enrolled at the HSCC are HIV-infected and 
antiretroviral treatment is started based on the prevailing South African national 
guidelines (34). The HSCC was chosen as the study site because it has one of the 
largest HIV paediatric cohorts in South Africa. This site is likely to be representative of 
urban paediatric HIV care in the South African public sector and patient records are 
conveniently stored electronically, allowing for efficient secondary data analysis. 
2.3 Study Population 
The study population consists of all HIV-infected children enrolled at the HSCC with at 
least 3 months of follow-up after ART initiation. 
. 
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2.4 Study Sample 
STATA version 11(STATA Corporation, College Station, TX) software package was 
used for power calculations. The Stata command stpower logrank can be used to 
estimate power for survival data when sample size and effect size (expressed as hazard 
ratio) are known. This command was used to plot power curves using the estimated 
sample size of 3000. (See Appendix 5 – Power Calculations for Sample Size) 
Using a total of 3000 patients, a two-sided test, and an alpha of 0.05, the statistical 
power was estimated to be more than 90% and would be able detect any significant 
difference in LTFU rates for all adjusted comparisons between predictors.  
2.4.1 Predictors of Loss to Follow-up Dataset 
The study sample consisted of 2536 children who initiated HAART at the Harriet Shezi 
Clinic between 1 April 2004 and 31 December 2008 and met the inclusion criteria 
described below. The study start date of April 1 2004 marks the beginning of the South 
African national antiretroviral roll-out programme when the HSCC started receiving 
government-sourced antiretroviral drugs. Children who had been started on donor-
sourced antiretroviral drugs prior to this date were excluded from the study. Children 
who were initiated on HAART after 31 December 2008 were excluded because they did 
not have adequate follow-up time (at least 9months) at database closure of 30 
September 2009. 
Inclusion Criteria: 
 Aged 12 years or less at time of HAART initiation 
 had been on HAART for at least 3 months at their last recorded clinic visit or at 
database closure (30 September 2009) 
Exclusion Criteria: 
 Had been on HAART for less than 3 months at their last recorded clinic visit or at 
database closure (30 September 2009) 
 Older than 12 years at HAART initiation 
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Those who had been on HAART for less than 3 months were excluded because of the 
high mortality during the first 3 months on HAART which can be perceived as LTFU. 
Children older than 12 years were excluded because adolescents may have unique 
characteristics and predictors to LTFU compared with younger children. Children who 
were transferred out or left ART care at HSCC during the study time period for other 
confirmed reasons were censored. 
2.4.2 Reasons for Clinic non-attendance Dataset 
A separate dataset created for the purposes of routine tracing of children who miss their 
scheduled appointments at the HSCC was used. The Defaulter Tracer database is 
based on the Defaulter tracer form (Appendix 1) which captures demographic 
information and telephonic responses given by caregivers when children who miss their 
visits are traced. All children enrolled at the HSCC who were ever traced for missing 
their appointments and had complete demographic information were included in the 
analysis. These children were traced between 18 June 2007 and 11 December 2010.  
The children had missed appointments between 17 June 2007 and 18 November 2010. 
A total of 3460 calls were made to trace 2244 children with complete records who had 
missed at least one scheduled appointment in the given time period. 
2.5 Data Management 
2.5.1 Measurement 
A multiple clerk and single entry databases created as part of routine clinical HAART 
care at Harriet Shezi clinic were used. These data were initially collected for the 
purposes of monitoring and evaluation of the Harriet Shezi paediatric HIV care 
programme under the ECHO paediatric clinics.  Demographic, clinical and laboratory 
data were entered into an electronic database by data clerks after every clinic visit. 
Data on reasons for clinic non-attendance was extracted from the Defaulter tracer 
database which was also created as part of routine care. (See Appendix 1: Defaulter 
tracer form Follow-up Question 1) Caregivers of children who had missed their 
scheduled appointments were contacted telephonically by trained counsellors and 
asked why the child had missed their visit. The counsellor recorded the responses on 
the form and this information was later entered into an electronic database by data 
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clerks. Most calls were made the same day the child missed their visit but if the 
caregiver could not be contacted, several attempts were made to contact the caregiver 
even 3 months after the last clinic visit. 
 
2.5.2 Study Variables 
Exposure Variables: Predictors of LTFU 
Demographic Characteristics 
 Age was defined as age of child at HAART initiation. It was calculated from Date 
of Birth and Date of HAART initiation. Age was categorized into the following 
categories: 0 – 11.9 months, 12 – 36.9 months, 36 – 59.9 months and 60 months 
to 12 years. Similar age-group categories are used in the World Health 
Organization (WHO) classification of HIV-associated immunodeficiency using 
CD4 percentage (35) in children and allow for comparison of levels of 
immunodeficiency in children of different ages. 
 Sex was defined as sex of child which was either male or female. 
 Primary caregiver relationship at HAART initiation was categorized into 4 
categories: mother, grandmother, other family members and other non-family 
(institutions, foster care, neighbours, and guardians). The role of the extended 
family and especially, grandmothers, in taking over the care of HIV-infected 
children in the event of HIV-related parental illness or death, has been well-
documented hence this classification(36-38). The number of children who had 
non-family members as their primary caregivers were also too few to allow any 
further classification. 
Clinical Features 
 Weight-for-age z-score (WAZ), Height-for-age z-score (HAZ) and Weight-for-
height z-score (WHZ) at HAART initiation: Z scores were calculated from 
baseline weight and height observations using the 1978 CDC/WHO growth 
reference curves and Epi Info Nutrition version 3.5.1 software. The more recent 
WHO 2007 reference charts go up to 10 years only for WAZ computation, since 
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WAZ needed to be calculated for all children aged 12 or less at baseline, they 
could not be used. Additionally, STATA S/E is required to run the WHO 2007 Do 
files. The student had the Student version of STATA, Stata I/C which does not 
have the capacity to run the 2007 Do files. Z scores are sex-independent and 
allowed for comparisons of levels of malnutrition across different sexes and age 
groups. WAZ, HAZ and WHZ were categorized into <-3, -2 to -3 and >-2. WHO 
Global Database on Child Growth and Malnutrition uses a Z-score cut-off point of 
<-2 for moderate malnutrition (underweight, stunting or wasting) and <-3 for 
severe malnutrition (underweight, stunting or wasting) (39).  
 CD4 cell % at HAART initiation was categorized into <15% and ≥ 15%.These 
percentages mean different severity of immunodeficiency depending on the age 
of the child. 
 Immune suppression is a variable that was created from age, CD4% and CD4 
cell count based on the WHO classification of HIV-associated immunodeficiency 
(Table 2.1). Immune suppression has two categories none/mild and 
advanced/severe immune suppression. 
Table 2.1: WHO Classification of HIV-associated Immunodeficiency using CD4 
Count 
Classification of  
HIV-associated 
Immunodeficiency 
                        Age-related CD4 Values 
 
 <11 months 
 
12 – 35 months 
 
36 – 59 months 
 
≥ 5 years  
Not Significant >35% >30% >25% >500 cells/mm³ 
Mild 30 – 35% 25 – 30% 20 – 25% 350 – 499 cells/mm³ 
Advanced 25 -29% 20 – 25% 15 – 19% 200 – 349 cells/mm³ 
Severe <25% <20% <15% <200 cells/mm³ 
or <15% 
Source: Management of HIV infection and antiretroviral therapy in infants and children: 
A clinical manual. World Health Organization, 2006.(35) 
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 Plasma HIV viral load at HAART initiation measured in copies/mL was classified 
into <100 000, 100 000 to 1 million and >1 million copies/mL. Logarithm10 of 
plasma HIV viral load at HAART initiation was analysed as a continuous variable. 
 WHO clinical stage at baseline was analysed as a binary variable with the 
categories WHO stage 1/2 and WHO stage 3/4. This was necessitated by the 
fact that the HSCC changed from the 3-stage WHO classification to the 4-stage 
WHO classification in late 2004, so children who were previously classified as 
stage 3 were now classified as stage 4.  
 Year of HAART initiation was analysed as a categorical variable with the 5 
categories; 2004, 2005, 2006, 2007 and 2008.  
 Tuberculosis at baseline was a binary variable with those who had ever had a 
diagnosis of TB (current or previous) and those who had not. 
 Initial regimen at initiation of treatment was categorised as NNRTI-based or PI-
based. 
Outcome Variables: Predictors of LTFU 
 Loss to Follow-up (LTFU): A child was defined as LTFU if their last date of 
contact with the clinic was more than 6 months before the date of database 
closure (30 September 2009) and were not known to have died or transferred.  
 TIFU (Temporary interruption of follow-up): A child returns to care after at least 6 
months of no contact with the clinic.  
Variables: Reasons for clinic non-attendance 
The reasons for missing scheduled clinic appointments were classified categorically 
according to the responses given when the caregivers were telephoned. 
2.5.3 Data Quality Control 
Range checks for outliers were done using histograms and box and whisker plots for 
continuous variables. Duplicates were removed from the dataset. Consistency checks to 
identify inconsistencies in the data were done e.g. checking whether dates of initial visit, 
initial viral load, CD4 count and ART initiation were all larger than date of birth.  
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2.5.4 Data Processing Methods and Analysis 
STATA version 11(STATA Corporation, College Station, TX) software package was 
used for all statistical analyses. All statistical significance was calculated at the 5% 
significance level. 
The study population variables were described and are presented in Table 1. Table 1 
also shows the proportion of missing values for each variable. Analysis of missing 
values using Chi-squared tests was done to investigate whether missing data were 
associated with the outcome (LTFU) and is presented in Appendix 2. 
 Categorical variables were described using frequency tables and their association with 
LTFU was tested using the Chi-squared test of proportions. Continuous variables were 
tested for the assumption of normality using histograms, normal quantile plots and 
standardised normal probability plots (Appendix 3). Normally distributed continuous 
variables were summarized in terms of mean and standard deviation and were tested 
for their association with LTFU using the Student’s t test. Non-normal continuous 
variables were summarized in terms of median and inter-quartile range and their 
association with LTFU was tested using the Wilcoxon rank-sum test. Pie charts and 
frequency tables were used to describe the reasons for clinic non-attendance. 
Time-to-event analysis was the primary method of analysis used. The time axis was 
years from HAART initiation and all children were censored at their last visit or on 30 
September 2009.Period incidence rates and cumulative probabilities of LTFU and TIFU 
at specified intervals were calculated. Kaplan-Meier estimates of LTFU and TIFU were 
determined. Logrank tests of equality of survival functions and trend tests were done to 
compare Kaplan Meier curves. Cox proportional hazards models were fitted to 
investigate associations between baseline characteristics and LTFU as well as TIFU. 
Global tests (using Schoenfeld residuals) and graphical tests for validity of the 
proportional hazards assumptions were done and are presented in Appendix 4. 
Variables with p value< 0.1 in univariate analysis were considered for the multivariate 
Cox models. These were added to the models starting with the one with the smallest p 
value. Variables which violated the proportional hazards assumption were excluded 
from the model. The final model had fewer variables with the smallest Wald test p value.  
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Accounting for Non-Proportional Hazards 
There are several approaches to dealing with departures from the proportional hazards 
assumption. These include stratifying analysis by the variable with the time-varying 
effect, partitioning the time axis and reporting hazard ratios for each time interval, 
abandoning the Cox model all together and using other statistical models such as 
additive models and restricting follow-up to a shorter time window in which the 
proportional hazards assumption holds (40). Additional models were run restricting 
follow-up time to 12 months and variables that violated the proportional hazards 
assumption were considered in these models. These are shown in Tables 6.1 and 10.1 
for LTFU and TIFU respectively. 
2.6 Ethical Considerations 
To protect the identities of participants, the datasets used unique patient identifiers and 
not patient names. Any other potential identifiers were removed from the datasets 
before they were provided for analysis. Data were stored in the student’s personal 
laptop which has password restricted access.  The information obtained from this study 
will be used to improve care at the Harriet Shezi clinic and at other paediatric ART sites 
in the country. Ethical approval was sought and was granted by the University of 
Witwatersrand ethics committee (Clearance Certificate M10940, approved 1st October 
2010, See attached copy of certificate on the last page).  
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Chapter 3: Results 
Introduction 
In this chapter, the results of the study are presented with the aim of fulfilling the 
objectives of the study. The chapter starts with a description of the overall cohort 
characteristics of the study sample. The incidence rates and cumulative probabilities of 
LTFU and TIFU are reported. Associations between LTFU and baseline variables are 
then explored and the predictors of LTFU identified. Similarly, associations between 
TIFU and exposure variables are investigated and predictors of TIFU are identified. The 
chapter ends with a description of the reasons given for clinic non-attendance. 
3.1 Cohort Description 
A total of 2937 children were initiated on HAART at HSSC between 01 April 2004 and 
31 December 2008. Of these, 190 were excluded because they were older than 12 
years at HAART initiation and 211 were excluded because at their last clinic visit they 
had been on HAART for less than 3 months. The remaining sample had 2536 children. 
A flow chart of children included in the study is shown in Figure 1. 
Table 1 summarizes the overall cohort characteristics of the study sample including the 
proportion of missing data for each variable. The variable weight-for-height z-score had 
the highest proportion of missing values with 27.29% of data missing. Missing data for 
all variables were not associated with LTFU, except for the variable sex (See Appendix 
2: Analysis of missing data) which only had 2 values missing (0.08%). 
The median age was 4.46 years (IQR 1.73 – 7.35) and 48.46% (1229) of the children 
were female. The majority of the children (59.03%) had mothers as their primary 
caregivers at HAART initiation. Most of the children had advanced/severe 
immunodeficiency (78.59%) at the start of treatment and 63.56% had WHO clinical 
stage 3 or 4. 
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Figure 1: Flow chart of HIV-infected children initiating HAART at HSCC between 
01 April 2004 and 31 December 2008 
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Table 1 : Overall Cohort Characteristics 
Characteristic  N                            %            
Sex  n ,% 
Male 
Female 
Data missing 
 
1305                    51.46 
1229                    48.46 
2                            0.08 
Age at HAART initiation  n ,%: 
0-11.9months 
12months-35.9months 
36months -59.9months 
60months-12years 
 
Median (IQR) 
 
410                      16.17 
550                      21.69 
430                      16.96 
1146                    45.19 
 
4.46 (1.73 – 7.35) 
Year of Starting HAART n ,% 
2004 
2005 
2006 
2007 
2008 
 
279                      11.00 
647                      25.51 
575                      22.67 
484                      19.09 
551                      21.73 
 Primary Caregiver  n ,% 
Mother 
Grandmother 
Other Family 
Foster Care/Institution/Neighbour/Guardian 
Data Missing 
 
1497                    59.03 
411                      16.21 
419                      16.52 
171                        6.74 
38                          1.50 
Weight-for-age Z score  n ,%: 
>-2  (Not underweight) 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
Data missing 
 
Mean (Standard Deviation) 
 
1022                    40.30 
512                      20.19 
398                      15.69 
604                      23.82 
 
-1.97 (1.28) 
Height-for-age Z score  n ,%: 
>-2  (No stunting) 
-2 to -3 (Moderate stunting) 
<-3  (Severe stunting) 
Data missing 
 
Mean (Standard Deviation) 
 
716                     28.23 
604                     23.82 
597                     23.54 
619                     24.41 
 
-2.41 (1.35) 
Weight-for-height Z score  n ,%: 
>-2  (No wasting) 
-2 to -3 (Moderate wasting) 
<-3 (Severe wasting) 
Data missing 
 
Mean (Standard Deviation) 
 
1596                   62.93 
173                       6.82 
75                         2.96 
692                     27.29 
 
-0.61 (1.29) 
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Immune suppression1  n ,%: 
Not significant/Mild 
Advanced/Severe 
Data missing 
 
105                       4.14 
1993                    78.59 
438                      17.27 
WHO Clinical Stage  n ,%:  
1/2 
3/4 
Data missing 
 
644                      25.39 
1612                    63.56 
280                      11.04 
TB prior to HAART  n ,% 
No 
Yes 
Data missing 
 
1457                    57.45 
1063                    41.92 
16                         0.63 
CD4 cell %  n ,%: 
< 15% 
≥ 15% 
Data missing 
 
Mean (Standard Deviation) 
 
682                      26.89 
1431                    56.43 
423                      16.68 
 
12.63 (7.93) 
Plasma Viral Load (copies/mL)  n ,% 
<100 000 
100 000 to 1 million 
> 1 million 
Data missing 
 
875                      34.50 
814                      32.10 
208                       8.20 
639                       25.20 
Log10 Viral Load  
Mean (Standard Deviation) 
 
11.67 (2.23) 
Initial Regimen 
NNRTI-based 
PI-based 
Data missing 
 
1620                     63.88 
900                       35.49 
16                          0.63 
1 WHO classification of HIV-related immunodeficiency in children according to age (See 
Table 2.1 for details) 
 
Table 2 shows baseline characteristics of children who were LTFU and those who were 
not. Log10 viral load, CD4 percentage, weight-for-age z-score, height-for-age z-score 
and weight-for-height z-score were normally distributed and Student’s t tests were done 
to test for differences between those LTFU and those who were not. Normality 
assumption tests are presented in Appendix 3. Age was not normally distributed and the 
Wilcoxon rank-sum test was done. Chi-squared tests were performed for all categorical 
variables. 
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Table 2 : Associations between Baseline Characteristics and LTFU (N=2536) 
Characteristic No Loss to Follow-up  Loss to Follow-up                                             P value1 
Sex (N=2534) n ,% 
Male 
Female 
 
1212                  92.87 
1149                  93.49 
 
93                   7.13 
80                   6.51 
 
 
0.538 
Age at HAART initiation (N=2536) n ,%: 
0-11.9months 
12months-35.9months 
36months -59.9months 
60months-12years 
 
Median (IQR) 
 
375                    91.46                     
497                    90.36 
404                    93.95 
1086                  94.76 
 
4.60 (1.79 – 7.43) 
 
35        8.54 
53                    9.64 
26                    6.05 
60                    5.24 
 
2.83 (1.21 – 5.53) 
 
 
 
0.003 
 
 
<0.001 
 Primary Caregiver (N=2498) n ,% 
Mother 
Grandmother 
Other Family 
Foster Care/Institution/Neighbour/Guardian 
 
1374                 91.78 
392                   95.38 
401                   95.70 
160                   93.57 
 
123                 8.22 
19                   4.62 
18                   4.30 
11                   6.43 
 
 
 
0.008 
Weight-for-age Z score (N=1932) n ,%: 
>-2  (Not underweight) 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
 
Mean (Standard Deviation) 
 
964                   94.32 
477                   93.16 
362                   90.95 
 
-1.96 (1.27) 
 
58                  5.68 
35                  6.84 
36                  9.05 
 
-2.17 (1.40) 
 
 
0.072 
 
 
0.073 
Height-for-age Z score (N=1917) n ,%: 
>-2  (No stunting) 
-2 to -3 (Moderate stunting) 
<-3  (Severe stunting) 
 
Mean (Standard Deviation) 
 
682                   95.25 
564                   93.38 
545                   91.29 
 
-2.40 (1.34) 
 
34                   4.75 
40                   6.62 
52                   8.71 
 
-2.66 (1.55) 
 
 
0.016 
 
 
0.037 
Weight-for-height Z score (N=1844) n ,%: 
>-2  (No wasting) 
-2 to -3 (Moderate wasting) 
<-3 (Severe wasting) 
 
Mean (Standard Deviation) 
 
1490                  93.36 
159                    91.91 
72                      96.00 
 
-0.61 (1.30) 
 
106                6.64 
14                  8.09 
3                    4.00 
 
-0.65 (1.18) 
 
 
0.491 
 
 
0.724 
Immune suppression2 (N=2098) n ,%: 
Not significant/Mild 
Advanced/Severe 
 
97                      92.38 
1860                  93.33 
 
8                    7.62 
133                6.67 
 
 
0.706 
WHO Clinical Stage (N=2256) n ,%:  
1/2 
3/4 
 
612                    95.03 
1491                  92.49 
 
32                   4.97 
121                 7.51 
 
 
0.030 
TB prior to HAART(N=2520)  n ,% 
No 
Yes 
 
1351                  92.72                 
996                    93.70 
 
106           7.28 
 67                  6.30 
 
 
0.340 
CD4 cell % (N=2113) n ,%: 
< 15% 
 
633                    92.82 
 
49                   7.18 
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≥ 15% 
 
Mean (Standard Deviation) 
1338                  93.50 
 
12.60 (7.91) 
93                   6.50 
 
12.91 (8.24) 
0.556 
 
0.656 
Plasma Viral Load (N=1897)(copies/mL)  n ,% 
<100 000 
100 000 to 1 million 
> 1 million 
 
831                    94.97 
750                    92.14 
190                    91.35 
 
44                   5.03 
64                   7.86 
18                   8.65 
 
 
0.030 
Log10 Viral Load (N=1897) 
Mean (Standard Deviation) 
 
11.64 (2.22) 
 
12.04 (2.35) 
 
0.046 
Initial Regimen (N=2520) n, % 
NNRTI-based 
PI-based 
 
1530                  94.44 
818                    90.89 
 
90                   5.56 
82                   9.11 
 
 
0.001 
1 P value for chi squared test for categorical variables, Student’s t test for normally 
distributed continuous variables and Wilcoxon Rank-sum test for non-normal continuous 
variables 
2 WHO classification of HIV-related immunodeficiency in children according to age (See 
Table 2.1 for details) 
The baseline median age among those who did not subsequently become LTFU was 
4.60 years (IQR 1.79 – 7.43) and was significantly higher than that of children who 
became LTFU (median 2.83 IQR 1.21 – 5.53, p<0.001). Children who became LTFU 
had lower baseline HAZ (mean-2.66 SD 1.55) compared to those who did not (mean-
2.40 SD 1.34, p=0.037). Those who became LTFU had higher log10 viral load (mean 
12.04 SD 2.22) compared to those who did not (mean 11.64 SD 2.35, p=0.046). 
The variables initial regimen, age group, plasma HIV viral load group, WHO clinical 
stage and primary caregiver relationship had significant associations with LTFU.  
3.2 Loss to Follow-up 
3.2.1 Overall Loss to Follow-up 
During the study period (01 April 2004 to 30 September 2008) a total of 174 children 
became lost to follow-up out of the 2536 enrolled between 01 April 2004 and 31 
December 2008. These children contributed a total of 6713.52 child-years and the 
overall incidence of LTFU during the entire study period was 2.59 per 100 child-years 
(95% CI 2.23 – 3.01).The median follow up time since ART initiation was 2.61 years 
(range 0.25 – 5.49 years). 
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Figure 2 and Table 3 show the Kaplan Meier cumulative probabilities of LTFU over the 
entire study period. The one-year and 2-year risk of LTFU were 2.85% (95% CI 2.26 – 
3.59) and 5.22% (95% CI 4.36 – 6.25) respectively. The five year cumulative probability 
of LTFU was 11.64% (95% CI 9.65 – 14.01). 
 
Figure 2 : Kaplan-Meier Estimates of Loss to Follow-up 
 
Table 3 : Cumulative Probability of LTFU 
Time Cumulative Probability of LTFU (%) (95%CI) 
6 months                  0.99    (0.67 – 1.47) 
12 months                  2.85    (2.26 – 3.59) 
18 months                  4.19    (3.44 – 5.09) 
2 years                  5.22    (4.36 – 6.25) 
2.5 years                  6.55    (5.54 – 7.73) 
3 years                  7.71    (6.57 – 9.04) 
3.5 years                  8.87    (7.59 – 10.36) 
4 years                  9.25    (7.91 -10.79) 
4.5 years                 10.15   (8.64 – 11.91) 
5 years                 11.64   (9.65 – 14.01) 
5.5 years                 11.64   (9.65 -14.01) 
 
Table 4 shows period incidence rates of LTFU at specified 6-month follow-up periods. 
The period incidence rate was initially high, being 3.73 per 100 child-years (95% CI 2.78 
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– 5.01) in the period 6 months – 1 year. From one year of follow-up to 3.5 years the 
period incidence rate varied little, ranging from 2.14 to 2.77 per 100 child-years. 
Thereafter it was erratic and there were fewer children who had been followed up for 
more than 3.5 years as reflected by decreasing person-time contributed and the wider 
confidence intervals of the LTFU rates. 
Table 4 : Period Incidence Rate of LTFU at specified times after HAART initiation 
Period 
 
Person-time in  
Child-years 
Failures 
(Number of children LTFU) 
LTFU Rate 
Per 100 child- years (95%CI) 
6 months – 1 year      1178.08                  44           3.73       (2.78 – 5.01) 
1 year – 18 months       1009.26                  28           2.77        (1.92 – 4.02) 
18 months – 2 years       839.52                  18          2.14        (1.35 – 3.40) 
2 years – 2.5 years       703.85                  20    2.84        (1.83 – 4.40) 
2.5 years – 3 years        597.42                  15    2.51        (1.51 – 4.16) 
3 years – 3.5 years       464.99                  12    2.58        (1.47 – 4.54) 
3.5 years – 4 years       346.15                   3    0.87        (0.27– 2.69) 
4 years – 4.5 years       215.47                   5    2.32        (0.97 – 5.57) 
4.5 years – 5 years        85.05                   4   4.70          (1.77 – 12.53) 
Total      6713.52                174    2.59         (2.23 – 3.01) 
 
3.2.2 Predictors of Loss to Follow-up 
Kaplan Meier estimates of the probability of LTFU by variables with significant log rank 
tests (p<0.05) are presented below Figures 3 to 6. Significant trend tests are also 
reported. 
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Figure 3 : Kaplan Meier estimates of LTFU by age group 
Younger children were more likely to become LTFU compared to older children. The 
logrank test of equality of survival functions was significant (p<0.001).The trend test was 
also significant p<0.001. 
 
Figure 4 : Kaplan Meier estimates of LTFU by initial regimen 
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Children who were initiated on a PI-based regimen (protease inhibitor) were more likely 
to become LTFU compared to those initiated on a NNRTI-based (non-nucleoside 
reverse transcriptase inhibitor) regimen. 
 
Figure 5 : Kaplan Meier estimates of LTFU by year of HAART initiation in the first 
year of follow-up 
Children who initiated HAART in 2007 and 2008 had a higher probability of LTFU than 
those who initiated HAART during or before 2006. The trend test was significant 
p=0.001. 
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Figure 6 : Kaplan Meier estimates of LTFU by primary caregiver relationship 
Children who had their mothers as primary caregivers at HAART initiation had the 
highest LTFU. Those in foster care or institutions had higher LTFU than those being 
taken care of by their grandmothers or other relatives. The trend test was significant 
p=0.001. 
 
Figure 7 : Kaplan Meier estimates of LTFU by WHO clinical stage 
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Children with more advanced clinical disease (WHO clinical stages 3 or 4) were more 
likely to be LTFU than those with WHO clinical stages 1 or 2. 
 
Figure 8 : Kaplan Meier estimates of LTFU by CD4 cell percentage 
Children with a CD4 cell percentage of less than 15 were less likely to become LTFU 
than those with CD4 percentage equal or greater to 15. 
 
Table 5 : Univariate Cox Proportional Hazards Model: LTFU 
Characteristic Hazard Ratio                    95% Confidence 
Interval 
P Value 
Sex (N=2534) 
Male 
Female 
 
1 
0.93 
 
 
0.69 – 1.25 
 
 
0.628 
Age Group at HAART initiation (N=2536)  
0-11.9months 
12months-35.9months 
36months -59.9months 
60months-12years 
 
1 
0.92 
0.54 
0.49 
 
 
0.60 – 1.41 
0.32 – 0.90 
0.32 – 0.74 
 
 
0.688 
0.018 
0.001 
Age at HAART initiation (continuous) 0.90 0.86 – 0.95 <0.001 
Year of Starting HAART1 (N=2536)  
2004 
2005 
2006 
2007 
2008 
 
1 
0.77 
1.28 
2.60 
2.16 
 
 
0.26 – 2.29 
0.45 – 3.58 
0.98 – 6.85 
0.81 – 5.76 
 
 
0.633 
0.644 
0.054 
0.124 
P=0.035
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 Primary Caregiver (N=2498) 
Mother 
Grandmother 
Other Family 
Foster Care/Institution/Neighbour/Guardian 
 
1 
0.48 
0.44 
0.67 
 
 
0.30 – 0.78 
0.27 – 0.72 
0.36 – 1.23 
 
 
0.003 
0.001 
0.196 
Weight-for-age Z score (N=1932) 
>-2  (Not underweight) 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
 
1 
1.16 
1.58 
 
 
0.76 – 1.76 
1.04 – 2.40 
 
 
0.492 
0.031 
Height-for-age Z score (N=1917) 
>-2  (No stunting) 
-2 to -3 (Moderate stunting) 
<-3  (Severe stunting) 
 
1 
1.31 
1.68 
 
 
0.83 – 2.08 
1.09 – 2.59 
 
 
0.242 
0.019 
Weight-for-height Z score (N=1844) 
>-2  (No wasting) 
-2 to -3 (Moderate wasting) 
<-3 (Severe wasting) 
 
1 
1.26 
0.61 
 
 
0.72 – 2.20 
0.19 – 1.92 
 
 
0.418 
0.397 
Immune suppression2 (N=2098)  
Not significant/Mild 
Advanced/Severe 
 
1 
0.70 
 
 
0.34 – 1.43 
 
 
0.325 
WHO Clinical Stage (N=2256)  
1/2 
3/4 
 
1 
2.34 
 
 
1.57 – 3.48 
 
 
<0.001 
TB prior to HAART(N=2520)  
No 
Yes 
 
1 
0.93 
 
 
0.69 – 1.27 
 
 
0.652 
CD4 cell % (N=2113)  
≥ 15% 
< 15% 
 
1 
0.69 
 
 
0.49 – 0.98 
 
 
0.036 
CD4 cell % (continuous) 0.99 0.97 – 1.03 0.896 
Plasma Viral Load (N=1897)(copies/mL)  
<100 000 
100 000 to 1 million 
> 1 million 
 
1 
1.42 
1.74 
 
 
0.97 – 2.08 
1.01 – 3.01 
 
 
0.075 
0.047 
Log10 Viral Load (N=1897) 1.07 0.98 – 1.16 0.116 
Initial Regimen (N=2520)  
NNRTI-based 
PI-based 
 
1 
1.93 
 
 
1.43 – 2.60 
 
 
<0.001 
1 Analysis of the variable “Year of HAART initiation” was restricted to 1 year of follow-up 
to minimize the effect of time on this variable 
2 WHO classification of HIV-related immunodeficiency in children according to age (See 
Table 2.1 for details) 
Cox proportional hazards models were fitted to identify predictors of LTFU. The variable 
primary caregiver relationship violated the proportional hazards assumption. All other 
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variables fulfilled the assumption of proportional hazards (See Appendix 4: Tests for 
proportional hazards assumption). The variable year of HAART initiation interacted with 
time and the analysis of this variable was restricted to the first year of follow-up. Table 5 
shows hazard ratios for each variable in univariate analysis. 
In univariate analysis, severe underweight (WAZ<-3), severe stunting (HAZ <-3) and 
WHO stage 3 or 4 were significantly associated with a greater risk of LTFU. Children 
who were severely underweight had a 58% greater chance of LTFU compared to those 
who were not underweight. Severely stunted children had a 68% greater risk of LTFU 
than children who were not stunted. Children who were WHO stage 3 or 4 were 2.34 
times more likely to become LTFU compared to those who were WHO stage 1 or 2 at 
baseline. 
Having a grandmother or other relatives as primary caregivers at baseline was 
significantly associated with a lower risk of LTFU than being cared for by one’s own 
mother. Older children were less likely to become LTFU, the hazard of LTFU decreasing 
by 10% for every 1 year increase in age. CD4 cell percentage of less than 15 was 
associated with a 31% less chance of LTFU. This association was lost when CD4 cell 
percentage was analysed as a continuous variable. Children with a plasma HIV viral 
load of greater than one million copies per ml were 1.74 times more likely to become 
LTFU than those with a viral load of less than 100 000 copies/ml. Children taking  PI-
based regimens were nearly twice as likely to become LTFU as those taking NNRTI-
based regimens. 
Year of HAART initiation was not associated with LTFU in the first year of follow-up. 
Sex of child, having TB prior to HAART initiation, weight-for-height z-score, immune 
suppression and log10 viral load had no significant association with LTFU in univariate 
analyses. 
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Table 6 : Multivariate Cox Proportional Hazards Model: LTFU 
Characteristic Hazard Ratio                    95% Confidence Interval P Value 
Age at HAART Initiation 0.91 0.84 – 0.99 0.026 
WHO Stage   
1/2 
3/4 
 
1 
2.14 
 
 
1.22 – 3.73 
 
 
0.008 
Height-for-age Z score   
>-2  (Not stunted) 
-2 to -3 (Moderately stunted) 
<-3 (Severely stunted) 
 
1 
1.10 
1.07 
 
 
0.65 – 1.85 
0.62 – 1.83 
 
 
0.725 
0.816 
CD4 cell % (N=2113)  
≥ 15% 
< 15% 
 
1 
0.67 
 
 
0.43 – 1.04 
 
 
0.075 
Plasma Viral Load (N=1897)(copies/mL)  
<100 000 
100 000 to 1 million 
> 1 million 
 
1 
1.40 
1.31 
 
 
0.87 – 2.24 
0.66 – 2.60 
 
 
0.167 
0.440 
 
Table 6 shows hazard ratios for variables included in the multivariate Cox proportional 
hazards model. The variable primary caregiver relationship was excluded from the 
model because it violated the proportional hazards assumption. Age and initial regimen 
were collinear since children were initiated on either a PI-based regimen or NNRTI-
based regimen according to their age. The variable regimen was thus excluded from the 
model. 
Young age and WHO clinical stage 3/4 independently predicted LTFU. Those with WHO 
clinical stage 3 or 4 were 2.14 times more likely to be LFTU compared to those who had 
WHO stage 1 or 2. Older children were less likely to become LTFU, the hazard of LTFU 
decreasing by 9% for every 1 year increase in age. Severe stunting, CD4 cell 
percentage ≥ 15 and plasma HIV viral load >1million copies/ml were longer associated 
with LTFU in the multivariate model. The global test for the overall model showed that 
the proportional hazards assumption had not been violated, p=0.898. 
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Table 6.1: Multivariate Cox Proportional Hazards Model Restricting Time to 1 
year: LTFU 
Characteristic Hazard Ratio                    95% Confidence Interval P Value 
Age at HAART Initiation 0.94 0.85 – 1.04 0.222 
WHO Stage   
1/2 
3/4 
 
1 
2.54 
 
 
1.06 – 6.09 
 
 
0.037 
CD4 cell %  
≥ 15% 
< 15% 
 
1 
0.48 
 
 
0.26 – 0.86 
 
 
0.014 
Primary Caregiver  
Mother 
Grandmother 
Other Family 
Foster Care/Institution/Neighbour/Guardian 
 
1 
0.27 
1.01 
0.89 
 
 
0.06 – 1.15 
0.46 – 2.24 
0.27 – 2.92 
 
 
0.076 
0.974 
0.852 
 
Table 6.1 shows a multivariate model in which follow-up time was restricted to the first 
12 months to account for non-proportional hazards. After restricting follow-up time to 12 
months, all variables met the proportional hazards assumption (See Appendix 4). WHO 
stage 3/4 and CD4% were significantly associated with LTFU. Age at HAART initiation 
no longer predicted LTFU after restricting follow-up time to 12 months.  
3.3 Temporary Interruption of Follow-up 
3.3.1 Overall Temporary Interruption of Follow-up 
During the study period (01 April 2004 to 30 September 2009) a total of 338 children 
ever temporarily interrupted follow-up (i.e. returned to care after absence from the clinic 
for at least 6 months). Only the first episode of TIFU per child was counted (single-
failure per subject analysis). 
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Figure 9 : Kaplan-Meier Estimates of Temporary Interruption of Follow-up 
Figure 9 and Table 7 show the Kaplan Meier cumulative probabilities of TIFU up to a 
maximum follow-up time of 5 years. The one-year and 2-year risk of TIFU were 2.29% 
(95% CI 1.76 – 2.98) and 9.21% (95% CI 8.0 – 10.58) respectively. The five year 
cumulative probability of TIFU was 25.47% (95% CI 22.47 – 28.79). The cumulative 
probability of TIFU rose steadily over time. 
Table 7 : Cumulative Probability of TIFU 
Time Cumulative Probability of TIFU (%) (95%CI) 
12months                  2.29    (1.76 – 2.98) 
2years                  9.21    (8.0 – 10.58) 
3years                  15.37  (13.72 – 17.21) 
4years                  21.08   (18.94 -23.42) 
5years                 25.47   (22.47 – 28.79) 
 
Table 8 shows period incidence rates of TIFU at 1 year follow-up periods up to a 
maximum follow-up time of 5 years. The period from 1 – 2 years had the highest 
incidence of TIFU [7.18 per 100 child-years (95% CI 6.04 – 8.53)] and the period from 0 
– 1 year had the lowest incidence of TIFU [2.22 per 100 child-years (95% CI 1.70 – 
0
.0
0
0
.1
0
0
.2
0
0
.3
0
0
.4
0
C
u
m
u
la
ti
v
e
 P
ro
b
a
b
ili
ty
 o
f 
T
IF
U
2536 1444 506 0 
Number at risk
0 2 4 6
Time from ART initiation in years
Overall TIFU
33 
 
2.90)]. The overall incidence of TIFU was 5.23 per 100 child-years (95% CI 4.70 – 
5.82). 
Table 8 : Period Incidence Rate of TIFU at Specified Times after HAART Initiation 
Period 
 
Person-time in  
Child-years 
Failures 
(Number of children 
TIFU) 
TIFU Rate 
Per 100 child-years (95%CI) 
0 months – 1 year      2430.18                  54          2.22       (1.70 – 2.90) 
1 year –  2 years      1796.62                  129           7.18        (6.04 – 8.53) 
2 years – 3 years      1216.55                  86         7.07        (5.72 – 8.73) 
3 years – 4 years       734.12                  51    6.95        (5.27 – 9.14) 
4 years – 5 years        267.74                  16    5.97       (3.66 – 9.75) 
Total      6458.06                338    5.23        (4.70 – 5.82) 
 
 
3.3.2 Predictors of Temporary Interruption of Follow-up 
Kaplan Meier estimates of the probability of TIFU by variables with significant log rank 
tests (p<0.05) are presented below in Figures 10 to 12. 
 
Figure 10 : Kaplan-Meier Estimates of TIFU by TB prior to HAART initiation 
Children who had ever had TB prior to HAART initiation were less likely to temporarily 
interrupt follow-up than those who had not. 
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Figure 11 : Kaplan-Meier Estimates of TIFU by WHO clinical stage 
Children with WHO clinical stages 3 or 4 had a greater risk of LTFU than those with 
WHO clinical stages 1 or 2. 
 
 
Figure 12 : Kaplan-Meier Estimates of TIFU by CD4 cell percentage 
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Children with CD4 cell percentage of ≥ 15% had higher risk of temporarily interrupting 
follow-up than those with CD4 cell percentage <15. 
 
Table 9 : Univariate Cox Proportional Hazards Model: TIFU 
Characteristic Hazard Ratio                    95% Confidence 
Interval 
P Value 
Sex (N=2534) 
Male 
Female 
 
1 
0.92 
 
 
0.74 – 1.14 
 
 
0.455 
Age Group at HAART initiation (N=2536)  
0-11.9months 
12months-35.9months 
36months -59.9months 
60months-12years 
 
1 
0.64 
0.48 
0.54 
 
 
0.46 – 0.88 
0.33 – 0.69 
0.40 – 0.72 
 
 
0.006 
<0.001 
<0.001 
Age at HAART initiation (continuous) 0.95 0.92 – 0.97 0.007 
Year of Starting HAART1 (N=2536)  
2004 
2005 
2006 
2007 
2008 
 
1 
0.79 
1.25 
1.02 
1.16 
 
 
0.29 – 2.13 
0.49 – 3.24 
0.37 – 2.81 
0.43 – 3.10 
 
 
0.640 
0.638 
0.968 
0.765 
 Primary Caregiver (N=2498) 
Mother 
Grandmother 
Other Family 
Foster Care/Institution/Neighbour/Guardian 
 
1 
0.52 
0.51 
0.78 
 
 
0.37 – 0.73 
0.36 – 0.71 
0.51 – 1.19 
 
 
<0.001 
<0.001 
0.249 
Weight-for-age Z score (N=1932) 
>-2  (Not underweight) 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
 
1 
0.73 
1.30 
 
 
0.51 – 1.04 
0.94 – 1.79 
 
 
0.080 
0.110 
Height-for-age Z score (N=1917) 
>-2  (No stunting) 
-2 to -3 (Moderate stunting) 
<-3  (Severe stunting) 
 
1 
1.11 
1.14 
 
 
0.79 – 1.56 
0.82 – 1.60 
 
 
0.560 
0.432 
Weight-for-height Z score (N=1844) 
>-2  (No wasting) 
-2 to -3 (Moderate wasting) 
<-3 (Severe wasting) 
 
1 
1.24 
1.47 
 
 
0.79 – 1.93 
0.82– 2.63 
 
 
0.346 
0.202 
Immune suppression2 (N=2098)  
Not significant/Mild 
Advanced/Severe 
 
1 
1.03 
 
 
0.55 – 1.93 
 
 
0.931 
WHO Clinical Stage (N=2256)  
1/2 
 
1 
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3/4 1.50 1.15 – 1.96 0.003 
TB prior to HAART(N=2520)  
No 
Yes 
 
1 
0.77 
 
 
0.62 – 0.97 
 
 
0.026 
CD4 cell % (N=2113)  
≥ 15% 
< 15% 
 
1 
0.74 
 
 
0.57 – 0.95 
 
 
0.018 
CD4 cell % (continuous) 0.99 0.97 – 1.03 0.896 
Plasma Viral Load (N=1897)(copies/mL)  
<100 000 
100 000 to 1 million 
> 1 million 
 
1 
1.15 
1.78 
 
 
0.87 – 1.51 
1.22 – 2.61 
 
 
0.317 
0.003 
Log10 Viral Load (N=1897) 1.08 1.01 – 1.14 0.016 
Initial Regimen (N=2520)  
NNRTI-based 
PI-based 
 
1 
1.49 
 
 
1.20 – 1.85 
 
 
<0.001 
1 Analysis of the variable “Year of HAART initiation” was restricted to 1 year of follow-up 
to minimize the effect of time on this variable 
2 WHO classification of HIV-related immunodeficiency in children according to age (See 
Table 2.1 for details) 
Cox proportional hazards models were fitted to identify predictors of TIFU. The variables 
age, plasma HIV viral load group and primary caregiver relationship violated the 
proportional hazards assumption. All other variables fulfilled the assumption of 
proportional hazards (See Appendix 4). Table 9 shows hazard ratios for each variable in 
univariate analyses. 
 WHO clinical stage, history of TB prior to HAART, CD4 cell percentage and log10 
plasma HIV viral load had significant associations with TIFU in univariate analysis. 
Children with WHO clinical stage 3/4 were 1.5 times more likely to interrupt follow-up 
than those with stages 1/2. Children with a positive history of TB prior to HAART 
initiation had a 23% less risk of TIFU than those without. Children on PI-based regimens 
had greater risk of TIFU than those on NNRTI-based regimens (HR 1.49 95% CI 1.20 – 
1.85, p<0.001). 
Sex of child, weight-for-height z-score, height-for-age z-score, weight-for-age z-score, 
year of HAART initiation and immune suppression had no significant association with 
TIFU in univariate analyses. 
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Table 10 : Multivariate Cox Proportional Hazards Model: TIFU 
Characteristic Hazard Ratio                    95% Confidence Interval P Value 
Log10 Viral Load (N=1897) 1.04 0.97 – 1.13 0.262 
WHO Stage   
1/2 
3/4 
 
1 
1.16 
 
 
0.81 – 1.66 
 
 
0.416 
TB prior to HAART(N=2520)  
No 
Yes 
 
1 
0.96 
 
 
0.70 – 1.30 
 
 
0.779 
CD4 cell % (N=2113)  
≥ 15% 
< 15% 
 
1 
0.76 
 
 
0.54 – 1.07 
 
 
0.115 
Weight-for-age Z score (N=1932) 
>-2  (Not underweight) 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
 
1 
0.66 
0.89 
 
 
0.45 – 0.99 
0.59 – 1.36 
 
 
0.043 
0.608 
Initial Regimen (N=2520)  
NNRTI-based 
PI-based 
 
1 
1.67 
 
 
1.18 – 2.35 
 
 
0.004 
 
Table 10 shows hazard ratios of variables which were included in the multivariate 
model. The variables age, plasma HIV viral load group and primary caregiver 
relationship were excluded from the model because they violated the proportional 
hazards assumption.  
Initiating HAART on a PI-based regimen and being moderately underweight 
independently predicted TIFU. WHO clinical stage, CD4 cell percentage and history of 
TB prior to HAART initiation no longer predicted TIFU in the multivariate model. The 
global test for the overall model was not significant (p=0.831). 
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Table 10.1: Multivariate Cox Proportional Hazards Model Restricting Time to 
1year: TIFU 
Characteristic Hazard Ratio                    95% Confidence Interval P Value 
WHO Stage   
1/2 
3/4 
 
1 
1.74 
 
 
0.56 – 5.4 
 
 
0.339 
CD4 cell % (N=2113)  
≥ 15% 
< 15% 
 
1 
0.81 
 
 
0.34 – 1.92 
 
 
0.632 
Weight-for-age Z score (N=1932) 
>-2  (Not underweight) 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
 
1 
0.82 
0.53 
 
 
0.29 – 2.31 
0.17 – 1.71 
 
 
0.711 
0.291 
Initial Regimen (N=2520)  
NNRTI-based 
PI-based 
 
1 
4.39 
 
 
1.72 – 11.22 
 
 
0.002 
 
Table 10.1 shows a multivariate model in which follow-up time was restricted to the first 
12 months to account for non-proportional hazards. After restricting follow-up time to 12 
months, all variables met the proportional hazards assumption (See Appendix 4). 
Children on a PI-based initial regimen were 4.39 times more likely to be temporarily 
interrupt follow-up compared to those on an NNRTI based regimen.  WAZ no longer 
predicted TIFU after restricting follow-up time to 12 months. 
3.4 Reasons for Clinic Non-attendance 
A total of 2244 children who had missed at least one clinic appointment were traced 
between 18 June 2007 and 11 December 2010.  The children had missed appointments 
between 17 June 2007 and 18 November 2010. There were 3460 recorded attempts to 
trace these children. Twelve percent (417) of the times, the caregivers could not be 
contacted. Reasons for failure to contact the caregivers recorded by the counsellors 
included: lack of documented contact details, wrong contact number, caregiver was not 
at home and a message was left and the phone not being answered. 
Figure 13 and Table 11 show the reasons given for missing a clinic appointment among 
those who were contacted.  
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Figure 13 : Reasons for Clinic non-attendance 
 
Table 11 : Reasons for Clinic non-attendance 
Reason for Clinic non-attendance Frequency Percentage 
Died 64 2.10 
Transferred 79 2.60 
Home Visit 290 9.53 
Booking Problems 152 5.00 
Misread/Forgot 457 15.02 
Child sick/admitted 101 3.32 
Financial Problems 327 10.75 
Social Problems 1413 46.43 
Lack of Information 112 3.68 
Transport Problems 14 0.46 
Government Strike 34 1.12 
Total 3043 100 
 
46.43%
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Transport Problems Government Strike
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Child Sick/Admitted Lack of Information
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The most common reasons for clinic non-attendance were social reasons (46.43%) and 
a further analysis of social reasons is given in Figure 14 and Table 12. After social 
reasons misreading or forgetting the clinic appointment accounted for 15.02%, followed 
by financial reasons (10.75%), home visits(i.e. clinic staff had visited child’s home and 
rebooked child or brought treatment) (9.53%) and booking problems (5.00%). Just over 
two percent had died and 2.60% were transfers. Other reasons given included lack of 
information, the child being sick or admitted, the public service strike in 2010 and 
transport problems. 
 
 
Figure 14 : Social Reasons for clinic non-attendance 
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Table 12 : Social Reasons for clinic non-attendance 
Social Reason Given Frequency Percentage 
Caregiver Problems 752 53.22 
School 102 7.22 
Funeral at home 171 12.10 
Away on holiday 272 19.25 
Unspecified social reasons 89 6.30 
Other specified social reasons 7 0.50 
Disclosure problems 20 1.42 
Total 1413 100 
 
Figure 14 and Table 12 show social reasons given for missing scheduled clinic visits. 
Caregiver-related problems (53.22%) were the commonest social reasons given for 
missing a clinic visit. Caregiver-related problems included the following:  the caregiver 
being committed elsewhere, sick, at work, not available, taking another child to the clinic 
and being arrested. Other caregiver-related problems included the child being orphaned 
and the lack of a committed caregiver and the child being forcefully taken from their 
place of residence by either of the parents. 
 Children being away on holiday accounted for 19.25% of social reasons. Other social 
reasons given included having a funeral at home (12.10%), schooling activities (7.22%) 
such as school trips or exams and disclosure problems (1.42%). More than six percent 
of the times the actual social reason given was not specified or documented and only 
the words “social reason” were recorded. Other specified social reasons which were 
less common included refusal of parent or child to come to the clinic, denial that the 
child actually had HIV infection and having a cleansing ritual ceremony at home. 
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Chapter 4: Discussion 
 
The study aimed to determine the rate of LTFU in children receiving ART and to identify 
baseline characteristics associated with LTFU and TIFU in these children. The findings 
of the study are discussed below with respect to each objective and the chapter ends 
with a discussion of possible limitations of the study. 
4.1 Baseline Characteristics 
As in other paediatric HIV care programmes (5, 8), the majority of children initiated 
HAART at advanced stages of the disease having WHO stage 3 or 4 and advanced or 
severe immune suppression.  The children who were LTFU were younger, had lower 
HAZ, higher log10 viral load, and were more likely to be WHO stage 3 or 4 and to have 
their mother as their primary caregiver. There are some similarities and differences in 
baseline characteristics of those LTFU with those found in other studies. Haitian 
children who were LTFU had lower baseline median WAZ (-3, IQR -3.7 to -1.8) than 
those who were not LTFU but had no other significant differences at baseline with those 
retained in care (25). The mean age at baseline of children who were lost to follow-up 
was lower (4.30 years) than that of children who were retained in care (6.14 years) in a 
study done in Lilongwe, Malawi (20). Findings in this study are consistent with the 
Malawian study with median age at baseline being lower in children who were LTFU. 
4.2 Loss to Follow-up 
4.2.1 Overall Loss to Follow-up 
The cumulative probabilities of LTFU at 6 months, 12 months and 2 years were found to 
be 0.9% (95% CI 0.67 – 1.47), 2.85% (95% CI 2.26 – 3.59) and 5.22% (95% CI 4.36 – 
6.25) respectively. These are much lower than those found in the KIDS ART LINC 
collaboration study which were 2.6% (95% CI 2.0 – 3.4), 5.0% (95% CI 4.1 – 6.1) and 
10.3% (95% CI 8.9 – 11.9) at 6 months, 12 months and 2 years respectively (7). This 
was probably because children who had been on HAART for less than 3 months at their 
last clinic visit were excluded in this study, reducing the effect of unreported deaths on 
LTFU. 
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4.2.2 Predictors of Loss to Follow-up 
In univariate analysis, younger age, severe stunting (HAZ <-3), severe underweight 
(WAZ <-3), WHO clinical stage 3 or 4, CD4 cell percentage greater than 15%, plasma 
HIV viral load of greater than one million copies/ml, being on a PI-based regimen and 
having one’s own mother as a primary caregiver predicted LTFU. After adjusting for  
WHO clinical stage, HAZ, age, CD4 percentage and viral load, independent predictors 
of LTFU were WHO clinical stage 3 or 4 and younger age. Advanced or severe immune 
suppression and weight-for-height z-score were not associated with LTFU. 
In the KIDS ART LINC collaboration, contrary to our findings, only severe clinical status 
(as per WHO age-specific categories) was significantly associated with LTFU (7). A 
study in Western Kenya by Braitstein et al found severe immune suppression (as per 
WHO age-specific categories), and severe weight-for-height z-score predictive of LTFU 
in unadjusted analysis (23). In the same study; older children (per year) and children 
enrolled in later time periods were less likely to be LTFU in univariate analysis. Severe 
immune suppression is the only predictor that remained significant in adjusted analysis 
in the same study (23). The finding that advanced or severe immune suppression does 
not predict LTFU sharply contrasts other findings. Severe immune suppression may be 
responsible for the high mortality in the first 3 months of HAART, since children with 
HAART duration of less than 3 months were excluded, the effect of unreported deaths 
on LTFU was less and severe immune suppression no longer predicted LTFU. The 
finding that younger children are more likely to become LTFU was similar to what 
Brainstien et al found. 
In a study of patient outcomes in the Thailand paediatric ART programme, WHO clinical 
stage C independently predicted LTFU (24). This is consistent with WHO stage 3 or 4 
independently predicting LTFU in our study. The study on outcomes of the South 
African paediatric national ART programme by the IeDEA-SA collaboration found that 
LTFU at one year increased from 2.2%(95% CI 1.1 – 4.7) in those who commenced 
HAART before 2004 to 8.2%(95% CI 7.1 – 9.4) in those who commenced treatment 
during or after 2006 (8). Similarly, the Kaplan Meier plot of LTFU in the first year on 
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HAART showed that children started on HAART in 2007 and 2008 were more likely to 
become LTFU compared to those started before or during 2006. 
The finding that children staying with their own mothers at baseline were more likely to 
be LTFU can be explained by the possibility that a significant number of these mothers 
could have died during the follow-up period resulting in the children becoming LTFU. 
 
4.3 Temporary Interruption of Follow-up 
4.3.1 Overall Temporary Interruption of Follow-up 
A total of 338 (13.33% of study sample) children interrupted follow-up for at least 6 
months before returning to care during the study period. This showed that LTFU is not 
necessarily permanent.  
The one-year and 2-year risk of TIFU were 2.29% (95% CI 1.76 – 2.98) and 9.21% 
(95% CI 8.0 – 10.58) respectively. The five year cumulative probability of TIFU was 
25.47% (95% CI 22.47 – 28.79). While there are no studies to compare with, risk of 
TIFU was high and rose steadily over time and this might have implications on 
development of resistance to antiretroviral drugs in patients who temporarily interrupt 
follow-up.  
Notably, there were very few episodes of TIFU in the first year of follow-up. The 
frequency of visits in the first year is much higher than in subsequent years and a 
shorter definition of TIFU in the first year might be appropriate. 
4.3.2 Predictors of Temporary Interruption of Follow-up 
In univariate analysis, viral load >1million copies/ml, younger age, not having TB prior to 
HAART initiation, WHO clinical stage, CD4% ≥ 15%, taking a PI-based regimen and 
having a mother as primary caregiver were associated with TIFU. In adjusted analysis, 
being moderately underweight and taking a PI-based independently predicted TIFU.  
4.4 Reasons for Clinic Non-attendance 
Reasons for failure to contact the caregivers included having no documented contact 
details, wrong contact number, caregiver was not at home and a message was left and 
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the phone not being answered. This just highlighted the need to have correctly 
recorded, detailed contact details and alternative contact numbers in patient files. 
Most reasons for loss to follow-up given in previous studies are socio-economic (14, 15, 
18, 29) and indeed social reasons (46.43%) and financial (10.05%) together accounted 
for the majority of reasons given. However, the reasons given were unique because the 
population was paediatric and the children were traced early and not after they had 
already been LTFU. Only 2.10% had died, but in some studies where adult patients are 
traced after LTFU mortality rates of 50% have been reported (18). Misreading or 
forgetting the clinic appointment accounted for 15.02% of reasons given. This may 
reflect on lack of commitment by caregivers or a need for innovative ways of reminding 
caregivers of clinic appointments e.g. bulk short message services sent to all caregivers 
a day before the clinic appointment. 
Caregiver-related problems (53.22%) were the commonest social reasons given for 
missing a clinic visit. The adherence of children has been shown to be dependent on 
characteristics of the caregiver and the relationship with the caregiver in previous 
studies (26). Details of the caregiver-related problems such as the caregiver being 
committed elsewhere, caregiver being sick, at work, not available and taking another 
child to the clinic; highlight the problems that caregivers of HIV-infected children face. 
HIV is a family disease and it is possible that other siblings of the child or parents might 
be infected and also needing care. There is need for caregivers to identify secondary 
caregivers who can take the child to the clinic in the event that the primary caregiver is 
unable to. Sometimes a child was forcefully taken from their place of residence by either 
of the parents. Where both parents of a child are alive, the parent who brings the child 
to the clinic should be encouraged to involve the other parent in the care of the child so 
that they are aware of the treatment needs of the child. 
Children being away on holiday accounted for 19.25% of social reasons and schooling 
activities such as school trips or exams accounted for 7.22%.This showed that HAART 
needs to be incorporated into the normal activities of lives of children living with HIV. 
There is need for proper planning between the clinic and the caregivers so that children 
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do not miss their visits for such reasons. Having a funeral at home accounted for 
12.10% of social reasons and this might reflect HIV deaths in the family. 
4.5 Limitations of the study 
This was an observational retrospective study using secondary data from routine ART 
services and only allows analysis of that which was collected. Some variables which 
can be potential confounders might not have been collected. Additionally, data were 
collected through a multiple clerk single entry database, and had some missing 
information. Sometimes the actual reason given for missing appointments was not 
specified or documented and only “social reason” was recorded. More detail could have 
shed more light. 
The WHO classification of malnutrition by z-score cut-off points of <-2 for moderate 
malnutrition (underweight, stunting or wasting) and <-3 for severe malnutrition 
(underweight, stunting or wasting), by definition, misclassifies 2.28% of children of 
normal nutrition in the reference population as moderately malnourished and 0.13% as 
severely malnourished (39) .This should be kept in mind when results of z-scores are 
interpreted. 
In this study, baseline characteristics were modelled to identify predictors of LTFU. After 
5 years of follow-up, baseline characteristics would not be as predictive as they would 
be with shorter follow-up durations. Models with time-varying co-variates would have 
better predicted LTFU especially at longer follow-up durations.  
There might be some residual effect of mortality on LTFU even after excluding those 
with less than 3 months follow-up on ART. The period incidence of LTFU remains high 
for the period 6 months to 1 year compared to subsequent periods and WHO stages 3 
or 4 (which is a marker of disease severity) predicted LTFU. These findings may reflect 
residual mortality. 
4.6 Generalisability 
The HSCC is one of the largest HIV paediatric cohorts in South Africa and is likely to be 
representative of urban paediatric HIV care in the South African public sector. However, 
the quality of care at a tertiary academic hospital is likely to be higher compared to that 
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at lower levels of care or that in the rural areas. Therefore caution should be taken when 
generalizing these results to HIV care programmes in rural settings. 
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Chapter 5: Conclusions and Recommendations 
 
5.1 Conclusions 
The cumulative probabilities of LTFU at 6 months, 12 months and 2 years were found to 
be 0.9% (95% CI 0.67 – 1.47), 2.85% (95% CI 2.26 – 3.59) and 5.22% (95% CI 4.36 – 
6.25) respectively .These are much lower than those found in studies where children on 
HAART duration less than 3 months were included and may reflect on true LTFU with 
minimal effect of unreported early mortality. 
 WHO clinical stage 3 or 4 and younger age independently predicted LTFU. 
Independent predictors of TIFU were moderate underweight and being on a PI-based 
regimen. LTFU is not necessarily permanent with 13.33% children interrupting follow-up 
for at least 6 months before returning to care during the study period. The main reasons 
why children miss clinic appointments are social. Caregiver-related problems are 
important reasons for clinic non-attendance in children on HAART. 
5.2 Recommendations 
Children with WHO stage 3 or 4 stages are more likely to become LTFU and this 
suggests that starting children on HAART in earlier disease stages may reduce LTFU. 
Strategies to improve LTFU need to target younger children and there is need for further 
research to investigate why young children are especially vulnerable to LTFU. 
While mortality and LTFU are important indicators of effectiveness of HIV care 
programmes, there is need to learn more about patients who temporarily interrupt 
follow-up. Caregivers of children who temporarily interrupt follow-up can potentially 
provide a unique opportunity for health workers to learn the true reasons why children 
get LTFU. Such caregivers may also be targeted for more intensive adherence 
counselling.  Further studies on the implications of TIFU on the development of 
resistance to antiretroviral drugs are needed and children who temporarily interrupt 
follow-up can be targeted for resistance testing in such studies. 
Children rely on their caregivers for treatment adherence and caregivers of HIV-infected 
children need support in the care of these children. Caregivers should be encouraged to 
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form support groups within their various communities to so that they can assist each 
other with care of children. Primary caregivers of children need to be encouraged to 
identify secondary caregivers who can bring the child to the clinic in the event that they 
cannot. Siblings of HIV-infected children need to be tested and if found to be HIV-
positive, enrolled at the same clinic and given same appointments dates. There is need 
for innovative ways of reminding caregivers of clinic appointments e.g. bulk short 
message services sent to all caregivers a day before the clinic appointment. Contact 
details of caregivers need to be documented correctly and alternative contact details 
should also be documented for efficient patient tracing. There is need for proper 
planning between the clinic and the caregivers so that children do not interrupt their 
treatment for reasons such as school trips, exams or holidays. 
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APPENDIX 2: Analysis of Missing Data 
 
Characteristic No Loss to Follow-up 
N                         % 
 Loss to Follow-up 
N                      %                                             
 P value 
Sex 
Non-missing 
Missing 
 
2361              93.17 
1                     50.00 
 
173                6.83 
1                    50.00 
 
 
0.016 
Primary Caregiver Relationship 
Non-missing 
Missing 
 
2327               93.15 
35                   92.11 
 
171               6.85 
3                   7.89                  
 
 
0.800
Weight-for-age Z-score 
Non-missing 
Missing 
 
1803                 93.32 
559                   92.55 
 
129                6.68 
45                  7.45 
 
 
0.512 
Height-for-age Z-score 
Non-missing 
Missing 
 
1791                 93.43 
571                   92.25 
 
126                6.57 
48                 7.75 
 
 
0.312 
Weight-for-height Z-score 
Non-missing 
Missing 
 
1721                 93.33 
641                   92.63 
 
123                6.67 
51                  7.37 
 
 
0.535 
WHO Clinical Stage 
Non-missing 
Missing 
 
2103                  93.22 
259                    92.50 
 
153                6.78 
21                  7.50 
 
 
0.654 
Immunosuppression1 
Non-missing 
Missing 
 
1957                  93.28 
405                    92.47 
 
141                 6.72 
33                   7.53 
 
 
0.540 
CD4 cell % 
Non-missing 
Missing 
 
1971                  93.28 
391                    92.43 
 
142                 6.72 
32                   7.57 
 
 
0.530 
Log10 Viral Load 
Non-missing 
Missing 
 
1771                  93.17 
591                    92.49 
 
126                 6.64 
48                   7.51 
 
 
0.452 
TB prior to HAART   
Non-missing 
Missing 
 
2347                  93.13 
15                      93.14 
 
173                 6.87 
1                     6.25 
 
 
0.923 
Initial Regimen 
Non-missing 
Missing 
 
2348                  93.17 
14                      87.50 
 
172                 6.83 
2                    12.50 
 
 
0.371 
1 WHO classification of HIV-related immunodeficiency in children according to age (See Table 2.1 for 
details) 
Missing data were not associated with LTFU except with respect to the variable “Sex”. 
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APPENDIX 3: Tests for Normality 
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APPENDIX 4: Tests for Proportional Hazards Assumptions 
 
Tests for Proportional Hazard Assumption LTFU 
Global Tests for Proportional Hazards Assumption: (estat phtest) 
Global tests for proportional hazards assumptions based on Schoenfeld residuals were 
done after fitting univariate Cox models on all co-variates. With the exception of primary 
caregiver relationship, all co-variates had p>0.05 indicating that the proportional 
hazards assumption was not violated. 
Characteristic P Value Global Test 
 for PH Assumption 
Sex  0.493 
Age Group at HAART Initiation 0.588 
Age 0.916 
Year of HAART Initiation 0.206 
Primary Caregiver Relationship 0.037 
Weight-for-age z-score group 0.393 
Height-for-age z-score group 0.943 
Weight-for-height z-score group 0.518 
TB prior to HAART Initiation 0.855 
WHO Stage 0.147 
Immunosuppression 0.433 
CD4 % group 0.709 
Log10 Viral Load 0.639 
Regimen 0.659 
Global test for overall multivariate model p=0.898 
Tests for Proportional Hazards Assumption after Restricting Follow-up Time to 1 
year: LTFU 
Characteristic P Value Global Test 
 for PH Assumption 
Age Group at HAART Initiation 0.787 
WHO Stage 0.767 
CD4 % group 0.547 
Primary Caregiver Relationship 
Grandmother 
Other Family 
Foster Care/Institution/Neighbour/Guardian 
 
0.395 
0.185 
0.256 
Global Test 0.570 
 
Graphical Assessment of Proportional Hazards Assumption: (stphplot) 
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The proportional hazards assumption was also assessed graphically by plotting –ln{-
ln(survival)} curves for each categorical variable by ln(analysis) time. 
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Assessment of Proportional Hazards Assumption through comparison of Kaplan- 
Meier observed retention curves with Cox predicted curves: (stcoxkm) 
The proportional hazards assumption was assessed by comparing Kaplan-Meier 
observed survival (retention) curves with Cox predicted curves for categorical variables. 
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Tests for Proportional Hazards Assumption: TIFU 
Characteristic P Value Global Test 
 for PH Assumption 
Sex 0.916 
Age Group at HAART Initiation 0.038* 
Age 0.014* 
Year of HAART Initiation 0.372 
Primary Caregiver Relationship 0.002* 
Weight-for-age z-score group 0.399 
Height-for-age z-score group 0.374 
Weight-for-height z-score  0.700 
TB prior to HAART Initiation 0.840 
WHO Stage 0.075 
Immunosuppression 0.194 
CD4 % group 0.397 
Log10 Viral Load 0.493 
Viral Load Group 0.009* 
Regimen 0.717 
 * Significant p value, proportional hazards assumption violated.  
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Age, age group, primary care giver relationship and viral load group violated 
proportional hazards assumption. 
Global test for multivariate model p=0.831 
Tests for Proportional Hazards Assumption after Restricting Follow-up Time to 1 
year: TIFU 
Characteristic P Value Global Test 
 for PH Assumption 
Weight-for-age z-score group 
-2 to -3 (Moderately underweight) 
<-3 (Severely underweight) 
 
0.384 
0.582 
WHO Stage 0.356 
CD4 % group 0.244 
Initial Regimen 0.546 
Global Test 0.502 
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APPENDIX 5: Power Calculations for Sample Size 
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